Effect of Transition to Long-acting Injectable Antipsychotic Treatment on Care Burden in Schizophrenia/Sizofrenide Uzun Etkili Enjektabl Antipsikotik Tedaviye Geçisin Bakim Yükü Üzerine Etkisi

• Published in: Psikiyatride güncel yaklaşimlar 2021-12, Vol.13 (S1), p.361
• Main Authors: Tozoglu, Elif Ozcan, Ozpolat, Gokhan
• Format: Article
• Language: Turkish
• Subjects: Care and treatment; Caregivers; Health aspects; Schizophrenia
• ISSN: 1309-0658
• DOI: 10.18863/pgy.991538

The main aim of this study is to investigate the difference of transition from oral to long-acting antipsychotic treatments on caregiver burden of patients with schizophrenia. Other factors that may be related to the burden were also discussed. Caregivers (n:138) of patients diagnosed with schizophrenia for at least one year and who received oral paliperidone or aripiprazole were included in the study. The Zarit Caregiver Burden Scale (ZCBS) and The Clinical Global Impression-Disease Severity (CGI-S) were administered at baseline and 1 year after switching to long-acting injectables. Demographic characteristics of caregivers and patients were evaluated to determine other factors associated with the burden. Significant decreases were found in the ZCBS and CGI-S scores after transitioning to long-acting injectable antipsychotics. When the groups using paliperidone and aripiprazole were compared; the decrease in ZCBS scores was not significant, the decrease in CGI-S scores was significant.Caregiver burden was positively correlated with patient's age, CGI-S score, time spent in the same house, duration of illness, and the number of hospitalizations. A significant negative correlation was found among the caregiver's age, educational level and income. In conclusion, in the present study the importance of switching to long-acting injectable antipsychotics, which is a modifiable factor, to reduce caregiver burden was emphasized. Keywords: Schizophrenia, long-acting injection treatment, caregiver, caregiver burden Bu çalismadaki temel amacimiz, oral tedaviden uzun etkili antipsikotik tedavilere geçisin sizofreni hastalarinda bakim veren yükü üzerinde olusturdugu farki arastirmaktir. Yükle ilgili olabilecek diger faktörler de tartisilmistir. Çalismaya en az bir yildir sizofreni tanisi almis ve oral paliperidon veya aripiprazol alan hastalarin bakicilari (n:138) dahil edildi. Zarit Bakici Yükü Ölçegi (ZBYÖ) ve Klinik Global Izlenim-Hastalik Siddeti (KGIÖ-S) ölçegi baslangiçta ve uzun etkili enjektabl antipsikotiklere geçisten 1 yil sonra uygulandi. Bakim yükü ile iliskili olabilecek diger faktörler de ele alindi. Uzun etkili enjekte edilebilir antipsikotiklere geçildikten sonra ZBYÖ ve KGIÖ-S puanlarinda anlamli düsüsler bulund. Paliperidon ve aripiprazol kullanan gruplar karsilastirildiginda; ZBYÖ puanlarindaki düsüs anlamli degilken, KGIÖ-S puanlarindaki düsüs anlamliydi. Bakim veren yükü, hastanin yasi, KGIÖ-S puani, ayni evde geçirilen süre, hastalik süresi ve ha